Impact of introduction of the 9-valent human papillomavirus vaccine on vaccination coverage of youth in North Carolina

被引:2
|
作者
Trogdon, Justin G. [1 ]
Shafer, Paul [1 ]
Lindsay, Brianna [2 ]
Coyne-Beasley, Tamera [3 ]
机构
[1] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Hlth Policy & Management, 1101 McGavran Greenberg Hall,Campus Box 7411, Chapel Hill, NC 27599 USA
[2] Univ Penn, Sch Arts & Sci, Philadelphia, PA 19104 USA
[3] Univ N Carolina, Dept Pediat, 260 MacNider Bldg,Campus Box 7220, Chapel Hill, NC 27599 USA
关键词
Human papillomavirus; Vaccination; Interrupted time series; AGED; 13-17; YEARS; COST-EFFECTIVENESS; UNITED-STATES; ADVISORY-COMMITTEE; HPV VACCINATION; CERVICAL-CANCER; POLIO ENDGAME; RECOMMENDATIONS; HEALTH;
D O I
10.1016/j.vaccine.2018.01.013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: The objective of this study was to evaluate the impact of introduction of 9vHPV vaccine on HPV vaccination uptake (doses per capita) and initiation (>= 1 doses), completion (>= 3 doses) and compliance (>= 3 doses within 12 months) by adolescents. Methods: We used a retrospective cohort analysis using North Carolina Immunization Registry (NCIR) data from January 2008 through October 2016. The sample included Vaccines for Children eligible adolescents aged 9 to 17 years in 2016, for whom the NCIR contains complete vaccination history. We applied an interrupted time series design to measure associations between ZIP Code Tabulation Area (ZCTA)-level HPV vaccination outcomes over time with the introduction of 9vHPV in North Carolina (NC) in July 2015. Results: Each outcome displayed a linear upward trend over time with large seasonal spikes near August of each year, corresponding to the time when adolescents often receive other vaccines required for school entry. After accounting for these underlying trends, introduction of 9vHPV was not associated with a change in publicly funded HPV vaccination rates in NC. Conclusions: Our results indicate that 9vHPV substituted for 4vHPV in the first year after release in NC, but the release of 9vHPV was not associated with an overall change in HPV vaccination. (C) 2018 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1304 / 1309
页数:6
相关论文
共 50 条
  • [31] Acceptability and readiness to promote human papillomavirus vaccination at ages 9-10 years: a feasibility study among North Carolina clinics
    Vielot, Nadja A.
    Lane, Robyn M.
    Loefstedt, Kaitlyn
    Cunningham, Jennifer L.
    Everson, Jason
    Tiller, Eli
    Patel, Sarah E. Johnson
    Smith, Jennifer S.
    PILOT AND FEASIBILITY STUDIES, 2023, 9 (01)
  • [32] Impact and Cost-effectiveness of 3 Doses of 9-Valent Human Papillomavirus (HPV) Vaccine Among US Females Previously Vaccinated With 4-Valent HPV Vaccine
    Chesson, Harrell W.
    Laprise, Jean-Francois
    Brisson, Marc
    Markowitz, Lauri E.
    JOURNAL OF INFECTIOUS DISEASES, 2016, 213 (11): : 1694 - 1700
  • [33] Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
    Mahumud, Rashidul Alam
    Alam, Khorshed
    Keramat, Syed Afroz
    Ormsby, Gail M.
    Dunn, Jeff
    Gow, Jeff
    PLOS ONE, 2020, 15 (06):
  • [34] Costs and Cost-Effectiveness of 9-Valent Human Papillomavirus (HPV) Vaccination in Two East African Countries
    Kiatpongsan, Sorapop
    Kim, Jane J.
    PLOS ONE, 2014, 9 (09):
  • [35] Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies
    Giuliano, Anna R.
    Palefsky, Joel M.
    Goldstone, Stephen E.
    Bornstein, Jacob
    De Coster, Ilse
    Guevara, Ana Maria
    Mogensen, Ole
    Schilling, Andrea
    Van Damme, Pierre
    Vandermeulen, Corinne
    Ellison, Misoo C.
    Group, Thomas
    Kaplan, Susan
    Lin, Jianxin
    Bonawitz, Rachael
    Luxembourg, Alain
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
  • [36] Safety and Immunogenicity of a 9-Valent Human Papillomavirus Vaccine Administered to 9-to 15-Year-Old Japanese Girls
    Iwata, Satoshi
    Murata, Shinya
    Han, Shi Rong
    Wakana, Akira
    Sawata, Miyuki
    Tanaka, Yoshiyuki
    JAPANESE JOURNAL OF INFECTIOUS DISEASES, 2017, 70 (04) : 368 - 373
  • [37] Geospatial Patterns in Human Papillomavirus Vaccination Uptake: Evidence from Uninsured and Publicly Insured Children in North Carolina
    Trogdon, Justin G.
    Ahn, Thomas
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2015, 24 (03) : 595 - 602
  • [38] The Impact of 9-Valent HPV Vaccination on Couple Infertility Prevention: A Comprehensive Review
    Ciavattini, Andrea
    Marconi, Chiara
    Giannella, Luca
    Delli Carpini, Giovanni
    Sopracordevole, Francesco
    Di Giuseppe, Jacopo
    FRONTIERS IN MEDICINE, 2021, 8
  • [39] Immunogenicity and Safety of the 9-Valent Human Papillomavirus Vaccine in Solid Organ Transplant Recipients and Adults Infected With Human Immunodeficiency Virus (HIV)
    Boey, Lise
    Curinckx, Ans
    Roelants, Mathieu
    Derdelinckx, Inge
    Van Wijngaerden, Eric
    De Munter, Paul
    Vos, Robin
    Kuypers, Dirk
    Van Cleemput, Johan
    Vandermeulen, Corinne
    CLINICAL INFECTIOUS DISEASES, 2021, 73 (03) : E661 - E671
  • [40] The impact of vaccination on gender equity: conceptual framework and human papillomavirus (HPV) vaccine case study
    Portnoy, Allison
    Clark, Samantha
    Ozawa, Sachiko
    Jit, Mark
    INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH, 2020, 19 (01)